The use of intranasal NEO100 as an agent to treat a neurological disease such as GBM is unique in that it suggests the feasibility of nasal brain delivery via the cranial nerves, thereby avoiding the obstacle presented by the BBB. This delivery method also reduces exposure through the systemic circulation, by that minimizing the systemic […]
NeOnc Technologies Holdings conducted a study to examine the effects of its NEO212 formulation in helping to block one of the key processes in cancer tumor growth. In tumor cells, the endothelial-to-mesenchymal transition (EndMT) supports the pro-angiogenic and invasive characteristics of glioblastoma multiforme (GBM). Blocking this process would be a promising approach to inhibit tumor […]
Glioblastoma multiforme (GBM) is a malignant brain tumor characterized by its extensive vascularity, aggressiveness, and invasiveness, where cell migration plays an important role in tumor progression. Its poor prognosis is associated with high recurrence, and resistance to the current standard of care chemotherapy, temozolomide (TMZ). Despite great progress made in surgery and therapies, there has […]
Despite the introduction of new therapies for multiple myeloma (MM), many patients are still dying from this disease and novel treatments are urgently needed. NeOnc Technologies Holdings, Inc. designed a novel hybrid molecule, called NEO214, that was generated by covalent conjugation of the natural monoterpene perillyl alcohol (POH), an inducer of endoplasmic reticulum (ER) stress, […]
